دورية أكاديمية
Role of adjuvant therapy in stage IIIC2 endometrial cancer
| العنوان: | Role of adjuvant therapy in stage IIIC2 endometrial cancer |
|---|---|
| المؤلفون: | Bogani G, Cappuccio S, Casarin J, Narasimhulu DMM, Cilby WA, Glaser GE, Weaver AL, McGree ME, Keeney GL, Weroha J, Petersen IA, Mariani A. |
| المساهمون: | Bogani, G, Cappuccio, S, Casarin, J, Narasimhulu, Dmm, Cilby, Wa, Glaser, Ge, Weaver, Al, Mcgree, Me, Keeney, Gl, Weroha, J, Petersen, Ia, Mariani, A. |
| بيانات النشر: | BMJ |
| سنة النشر: | 2020 |
| المجموعة: | Sapienza Università di Roma: CINECA IRIS |
| مصطلحات موضوعية: | radiotherapy, endometrial cancer, metastases |
| الوصف: | Objective: The role of the different types of adjuvant treatments in endometrial cancer with para-aortic node metastases is unclear. The aim of this study was to report oncologic outcomes after adjuvant therapy in patients with stage IIIC2 endometrial cancer. Methods: This retrospective single-institution study assessed patients with stage IIIC2 endometrial cancer who underwent primary surgery from January 1984 to December 2014. All patients had hysterectomy (±salpingo-oophorectomy) plus lymphadenectomy (para-aortic nodes, ±pelvic nodes). We included all patients with stage III endometrial cancer and documented para-aortic lymph node metastases (International Federation of Obstetrics and Gynecologists stage IIIC2). We excluded patients who did not provide consent, who had synchronous cancer, or who underwent neoadjuvant chemotherapy. Follow-up was restricted to the first 5 years post-operatively. Cox proportional hazards models, with age as the time scale, was used to evaluate associations of risk factors with disease-free survival and overall survival. Results: Among 105 patients with documented adjuvant therapy, external beam radiotherapy was administered to 25 patients (24%), chemotherapy to 24 (23%), and a combination (chemotherapy and external beam radiotherapy) to 56 (53%) patients. Most patients receiving chemotherapy and external beam radiotherapy (80%) had chemotherapy first. The majority of relapses had a distant component (31/46, 67%) and only one patient had an isolated para-aortic recurrence. Non-endometrioid subtypes had poorer disease-free survival (HR 2.57; 95% CI 1.38 to 4.78) and poorer overall survival (HR 2.00; 95% CI 1.09 to 3.65) compared with endometrioid. Among patients with endometrioid histology (n=60), chemotherapy and external beam radiotherapy improved disease-free survival (HR 0.22; 95% CI 0.07 to 0.71) and overall survival (HR 0.28; 95% CI 0.09 to 0.89) compared with chemotherapy or external beam radiotherapy alone. Combination therapy did not improve prognosis for patients with ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/32646864; info:eu-repo/semantics/altIdentifier/wos/WOS:000561315100015; volume:30; issue:8; firstpage:1169; lastpage:1176; numberofpages:8; journal:INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER; http://hdl.handle.net/11573/1584297Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85087923529 |
| DOI: | 10.1136/ijgc-2020-001446 |
| الإتاحة: | https://doi.org/10.1136/ijgc-2020-001446Test http://hdl.handle.net/11573/1584297Test |
| رقم الانضمام: | edsbas.61717481 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/ijgc-2020-001446 |
|---|